The Experts below are selected from a list of 8421 Experts worldwide ranked by ideXlab platform
Marcelo B Sztein - One of the best experts on this subject based on the ideXlab platform.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
Takehiro Tanaka - One of the best experts on this subject based on the ideXlab platform.
-
villous atrophy in the Terminal Ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft versus host disease after allo hematopoietic stem cell transplantation
BMC Gastroenterology, 2018Co-Authors: Yuusaku Sugihara, Sakiko Hiraoka, Nobuharu Fujii, Shiho Takashima, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Takehiro TanakaAbstract:Graft-versus-host disease (GVHD) is a common complication of allo-hematopoietic stem cell transplantation (allo-HSCT). Endoscopic biopsy can provide a definitive diagnosis, but the optimal endoscopic approach for diagnosis remains uncertain. This study evaluated whether ileocolonoscopic imaging can predict acute GVHD severity after allo-HSCT. Consecutive patients who underwent allo-HSCT were referred to our institution, and those diagnosed with acute GVHD by pathology were included in this retrospective study. Fifty-one of 261 patients who underwent ileocolonoscopy were suspected to have acute intestinal GVHD. We performed univariate and multivariate conditional logistic regression with stepwise variable selection; villous atrophy in the Terminal Ileum remained a statistically significant predictor of GVHD severity (odds ratio, 4.69; 95% confidence interval, 1.07–20.60, P = 0.04). Patients were classified into three groups based on ileal endoscopic findings in the Terminal Ileum: group S, GVHD with severe villous atrophy; group M, mild atrophy; and group N, no atrophy. Compared with patients in groups M and N, those in group S had significant clinical GVHD at diagnosis (P = 0.03). In group S, three of four, compared with five of 13 patients in groups M and N, required the addition of second-line agents (P = 0.02). This study showed that severe atrophy of the Terminal Ileum predicts severe clinical GVHD that is likely to be refractory to steroid treatment. Thus, the severity of Terminal Ileum atrophy may serve as a tool in predicting clinically severe GVHD. Trial Registration Number UMIN 000022805 , Registration date July 1, 2016.
-
Villous atrophy in the Terminal Ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft-versus-host disease after allo-hematopoietic stem cell transplantation
'Springer Science and Business Media LLC', 2018Co-Authors: Yuusaku Sugihara, Sakiko Hiraoka, Nobuharu Fujii, Shiho Takashima, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Takehiro TanakaAbstract:Abstract Background Graft-versus-host disease (GVHD) is a common complication of allo-hematopoietic stem cell transplantation (allo-HSCT). Endoscopic biopsy can provide a definitive diagnosis, but the optimal endoscopic approach for diagnosis remains uncertain. This study evaluated whether ileocolonoscopic imaging can predict acute GVHD severity after allo-HSCT. Methods Consecutive patients who underwent allo-HSCT were referred to our institution, and those diagnosed with acute GVHD by pathology were included in this retrospective study. Results Fifty-one of 261 patients who underwent ileocolonoscopy were suspected to have acute intestinal GVHD. We performed univariate and multivariate conditional logistic regression with stepwise variable selection; villous atrophy in the Terminal Ileum remained a statistically significant predictor of GVHD severity (odds ratio, 4.69; 95% confidence interval, 1.07–20.60, P = 0.04). Patients were classified into three groups based on ileal endoscopic findings in the Terminal Ileum: group S, GVHD with severe villous atrophy; group M, mild atrophy; and group N, no atrophy. Compared with patients in groups M and N, those in group S had significant clinical GVHD at diagnosis (P = 0.03). In group S, three of four, compared with five of 13 patients in groups M and N, required the addition of second-line agents (P = 0.02). Conclusions This study showed that severe atrophy of the Terminal Ileum predicts severe clinical GVHD that is likely to be refractory to steroid treatment. Thus, the severity of Terminal Ileum atrophy may serve as a tool in predicting clinically severe GVHD. Trial registration Trial Registration Number UMIN 000022805, Registration date July 1, 2016
Jayaum S Booth - One of the best experts on this subject based on the ideXlab platform.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
Yuusaku Sugihara - One of the best experts on this subject based on the ideXlab platform.
-
villous atrophy in the Terminal Ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft versus host disease after allo hematopoietic stem cell transplantation
BMC Gastroenterology, 2018Co-Authors: Yuusaku Sugihara, Sakiko Hiraoka, Nobuharu Fujii, Shiho Takashima, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Takehiro TanakaAbstract:Graft-versus-host disease (GVHD) is a common complication of allo-hematopoietic stem cell transplantation (allo-HSCT). Endoscopic biopsy can provide a definitive diagnosis, but the optimal endoscopic approach for diagnosis remains uncertain. This study evaluated whether ileocolonoscopic imaging can predict acute GVHD severity after allo-HSCT. Consecutive patients who underwent allo-HSCT were referred to our institution, and those diagnosed with acute GVHD by pathology were included in this retrospective study. Fifty-one of 261 patients who underwent ileocolonoscopy were suspected to have acute intestinal GVHD. We performed univariate and multivariate conditional logistic regression with stepwise variable selection; villous atrophy in the Terminal Ileum remained a statistically significant predictor of GVHD severity (odds ratio, 4.69; 95% confidence interval, 1.07–20.60, P = 0.04). Patients were classified into three groups based on ileal endoscopic findings in the Terminal Ileum: group S, GVHD with severe villous atrophy; group M, mild atrophy; and group N, no atrophy. Compared with patients in groups M and N, those in group S had significant clinical GVHD at diagnosis (P = 0.03). In group S, three of four, compared with five of 13 patients in groups M and N, required the addition of second-line agents (P = 0.02). This study showed that severe atrophy of the Terminal Ileum predicts severe clinical GVHD that is likely to be refractory to steroid treatment. Thus, the severity of Terminal Ileum atrophy may serve as a tool in predicting clinically severe GVHD. Trial Registration Number UMIN 000022805 , Registration date July 1, 2016.
-
Villous atrophy in the Terminal Ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft-versus-host disease after allo-hematopoietic stem cell transplantation
'Springer Science and Business Media LLC', 2018Co-Authors: Yuusaku Sugihara, Sakiko Hiraoka, Nobuharu Fujii, Shiho Takashima, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Takehiro TanakaAbstract:Abstract Background Graft-versus-host disease (GVHD) is a common complication of allo-hematopoietic stem cell transplantation (allo-HSCT). Endoscopic biopsy can provide a definitive diagnosis, but the optimal endoscopic approach for diagnosis remains uncertain. This study evaluated whether ileocolonoscopic imaging can predict acute GVHD severity after allo-HSCT. Methods Consecutive patients who underwent allo-HSCT were referred to our institution, and those diagnosed with acute GVHD by pathology were included in this retrospective study. Results Fifty-one of 261 patients who underwent ileocolonoscopy were suspected to have acute intestinal GVHD. We performed univariate and multivariate conditional logistic regression with stepwise variable selection; villous atrophy in the Terminal Ileum remained a statistically significant predictor of GVHD severity (odds ratio, 4.69; 95% confidence interval, 1.07–20.60, P = 0.04). Patients were classified into three groups based on ileal endoscopic findings in the Terminal Ileum: group S, GVHD with severe villous atrophy; group M, mild atrophy; and group N, no atrophy. Compared with patients in groups M and N, those in group S had significant clinical GVHD at diagnosis (P = 0.03). In group S, three of four, compared with five of 13 patients in groups M and N, required the addition of second-line agents (P = 0.02). Conclusions This study showed that severe atrophy of the Terminal Ileum predicts severe clinical GVHD that is likely to be refractory to steroid treatment. Thus, the severity of Terminal Ileum atrophy may serve as a tool in predicting clinically severe GVHD. Trial registration Trial Registration Number UMIN 000022805, Registration date July 1, 2016
Claire M. Fraser - One of the best experts on this subject based on the ideXlab platform.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
-
systemic and Terminal Ileum mucosal immunity elicited by oral immunization with the ty21a typhoid vaccine in humans
Cellular and molecular gastroenterology and hepatology, 2017Co-Authors: Jayaum S Booth, Seema A Patil, Robin S Barnes, Bruce D Greenwald, Leyla Ghazi, Alessio Fasano, Claire M. Fraser, Marcelo B SzteinAbstract:Background & Aims Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (Terminal Ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on Terminal Ileum–lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. Methods We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)–specific responses by multichromatic flow cytometry. Results No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi–specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi–specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+ S Typhi–specific responses were unique and distinct from their systemic counterparts. Conclusions This study provides the first demonstration of S Typhi–specific responses in the human Terminal Ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
